Abstract
Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Current Enzyme Inhibition
Title: Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Volume: 6 Issue: 2
Author(s): Hai-Chun Yang, Yiqin Zuo and Agnes B. Fogo
Affiliation:
Keywords: TGF-β, kidney, fibrosis
Abstract: Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Export Options
About this article
Cite this article as:
Yang Hai-Chun, Zuo Yiqin and B. Fogo Agnes, Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?, Current Enzyme Inhibition 2010; 6 (2) . https://dx.doi.org/10.2174/157340810791233042
DOI https://dx.doi.org/10.2174/157340810791233042 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analytical Methods for the Determination of Sartans in Pharmaceutical Formulations and Biological Fluids: A Review
Current Analytical Chemistry Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Educating Scientists in Translational and Entrepreneurial Medicine: Unmet Needs and Challenges
Technology Transfer and Entrepreneurship (Discontinued) Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Current Diabetes Reviews Role of Ultrasonography in Acute Appendicitis of the Elderly. A Pictorial Essay
Current Medical Imaging Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic: Opportunities and Potential Challenges for the Treatment of Metabolic Syndrome (Guest Editors: Kak-Shan Shia and Yu-Sheng Chao)]
Current Topics in Medicinal Chemistry L-Type Calcium Channels
Current Pharmaceutical Design Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Most Efficient Routes for the Synthesis of α,β-Diamino Acid-Derived Compounds
Current Pharmaceutical Design Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design Simulating Physiology and Methods for Therapeutic Evaluation with Emphasis on Hypertension
Current Topics in Medicinal Chemistry Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Fluocinolone Acetonide Implantable Device for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science